In lung, prostate, renal, breast, endometrial, and pancreatic cancer cells, low doses of IFNγ in the tumor microenvironment, generated by host immune cells or during cytokine therapy, may in fact favor tumor progression [53]. The gene discussed is IFNG; the disease is neoplasm.